 BetterLife Pharma Inc CSE:BETR, OTCQB:BETRF reported positive findings from pre-clinical studies on mice, which showed the therapeutic potential of its 2-bromo-LSD TD-0148A candidate as an anti-depressant. TD-0148A is a second-generation Lysergic Acid Diethylamide LSD derivative molecule that BetterLife believes will mimic the therapeutic potential of LSD without causing psychedelic effects. 